S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.57
+1.89
+11.33%
RGNX · REGENXBIO Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
$7.17
-0.23
(-3.11%)
● At close: October 21 at 4:00:00 PM EDT
$7.20
+0.03
(+0.42%)
Pre-Market:
5:32:51 AM EDT
DAY'S RANGE
$7.17
$7.16
$7.45
52-WEEK RANGE
$7.17
$5.46
$16.19
What's happening
- RGNX is down 3.11% today, trading at $7.17. — Live quote
- Volume today (45,915) is well below its 3-month average of 1,810,390. (Finnhub fundamentals)
- Reports earnings on 2026-11-11 (after market close), 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $0.43 actual vs. $0.06 estimated (+626.4%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 6
Buy 9
Hold 3
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (18 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
RGNX
-48.61%
vs S&P 500
-61.39%
1-YEAR RETURN
RGNX
-41.46%
vs S&P 500
-56.02%
6-MONTH RETURN
RGNX
-19.48%
3-MONTH RETURN
RGNX
-28.43%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$0.43
Est. $0.06
BEAT +626.4%
2026-04-26 (Q1 2026)
$-1.72
Est. $-1.37
MISS -25.9%
2026-01-26 (Q4 2025)
$-1.30
Est. $-0.98
MISS -33.3%
2025-10-26 (Q3 2025)
$-1.20
Est. $-1.33
BEAT +9.9%
Valuation Measures & Ratios
Enterprise Value4$628.9M
Forward P/E5—
PEG Ratio6-0.21
Price / Sales (TTM1)2.77
Price / Book78.63
EV4 / Revenue3.60
EV4 / EBITDA5.24
Profit Margin-112.58%
Operating Margin-94.08%
Return on Equity (ROE8)-220.07%
Return on Assets (ROA9)-46.04%
Avg Volume (3M)1,810,390
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $632.4M | $438.2M | $498.6M | $421.6M | $363.7M |
| P/E | -3.16 | -2.02 | -2.68 | -2.38 | -2.14 |
| Price/Sales | 3.82 | 2.99 | 3.03 | 2.69 | 2.41 |
| Price/Book | 8.81 | 20.79 | 3.09 | 1.97 | 1.33 |
| EV/Revenue | 3.60 | 2.89 | 2.68 | 2.18 | 1.55 |
| ROE | -278.90% | -1028.27% | -115.41% | -83.01% | -61.94% |
| ROA | -51.77% | -63.41% | -35.48% | -30.53% | -34.59% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short9,608,992
Change from Prior Settlement+21.21%
% of Float—
Days to Cover (Short Ratio)5.99
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 405.7% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-10-16; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -112.6%. Finnhub fundamentals ↗
- Trailing 52-week price return is -41.5%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on RGNX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $108.0M | $6.4M | $29.7M | $21.4M | $89.0M | $24.2M | $22.3M | $15.6M |
| Operating income | $29.3M | -$83.4M | -$52.4M | -$63.3M | $12.1M | -$62.1M | -$56.0M | -$63.9M |
| Net income | $22.7M | -$90.1M | -$61.9M | -$70.9M | $6.1M | -$59.6M | -$53.0M | -$63.3M |
| EPS (diluted) | $0.43 | $-1.72 | $-1.20 | $-1.38 | $0.12 | $-1.17 | $-1.05 | $-1.38 |
| EPS (basic) | $0.43 | $-1.72 | $-1.20 | $-1.38 | $0.12 | $-1.17 | $-1.05 | $-1.38 |
| Operating margin | $27 | -$1.3K | -$176 | -$296 | $14 | -$257 | -$251 | -$409 |
| Net margin | $21 | -$1.4K | -$208 | -$332 | $7 | -$246 | -$238 | -$405 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $386.6M | $341.9M | $453.0M | $525.2M | $581.0M | $490.9M | $466.0M | $519.1M |
| Total liabilities | $314.9M | $320.8M | $350.3M | $363.8M | $367.3M | $216.7M | $206.3M | $217.7M |
| Stockholders' equity | $71.8M | $21.1M | $102.7M | $161.5M | $213.7M | $274.2M | $259.7M | $301.4M |
| Total current assets | $236.2M | $186.5M | $281.3M | $332.0M | $373.8M | $313.2M | $278.0M | $313.4M |
| Total current liabilities | $82.6M | $71.1M | $118.1M | $124.6M | $119.5M | $106.7M | $103.2M | $102.7M |
| Cash & equivalents | $36.5M | $15.2M | $34.5M | $58.8M | $79.6M | $130.1M | $57.5M | $56.6M |
| Marketable securities (current) | $69.0M | $135.3M | $195.6M | $215.4M | $243.7M | $137.8M | $177.2M | $198.8M |
| Accounts receivable | $106.8M | $10.0M | $26.4M | $25.3M | $20.2M | $18.2M | $20.5M | $23.6M |
| Other current assets | $11.8M | $14.4M | $12.9M | $19.5M | $19.5M | $16.1M | $13.8M | $16.1M |
| Marketable securities (non-current) | — | — | $10.8M | $27.8M | $40.3M | $4.9M | $10.2M | $23.1M |
| Property, plant & equipment | $98.5M | $101.9M | $104.9M | $107.5M | $111.0M | $114.5M | $117.6M | $120.6M |
| Other non-current assets | $5.9M | $5.5M | $4.6M | $4.3M | $1.9M | $3.0M | $4.0M | $4.3M |
| Accounts payable | $15.5M | $21.2M | $21.4M | $22.3M | $21.7M | $19.0M | $22.8M | $19.5M |
| Accrued liabilities | — | — | — | — | — | — | — | — |
| Deferred revenue (current) | $9.9M | $5.9M | $10.5M | $13.2M | $14.0M | $13.6M | $115.0K | $144.0K |
| Other non-current liabilities | $486.0K | $622.0K | $638.0K | $648.0K | $664.0K | $680.0K | $3.6M | $3.6M |
| Common stock & paid-in capital | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K |
| Retained earnings | -$1.19B | -$1.22B | -$1.13B | -$1.06B | -$996.9M | -$926.1M | -$932.1M | -$881.0M |
| Accumulated other comprehensive income (loss) | -$875.0K | -$870.0K | -$687.0K | -$652.0K | -$750.0K | -$762.0K | -$741.0K | -$582.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$62.2M | -$76.2M | -$52.3M | -$56.0M | -$49.3M | $33.6M | -$31.6M | -$40.5M |
| Investing cash flow | $65.9M | $70.6M | $37.5M | $42.3M | -$140.4M | $44.7M | $40.3M | $50.3M |
| Financing cash flow | $17.6M | -$13.6M | -$9.6M | -$7.1M | $139.2M | -$5.8M | -$7.7M | -$10.9M |
| Free cash flow | -$63.0M | -$77.4M | -$52.8M | -$56.5M | -$49.7M | $32.6M | -$32.7M | -$40.9M |
| Capital expenditures | $760.0K | $1.2M | $508.0K | $491.0K | $391.0K | $1.0M | $1.1M | $326.0K |
| Share-based compensation | $9.1M | $8.6M | $8.4M | $9.0M | $8.7M | $8.5M | $9.5M | $9.9M |
| Deferred income taxes | — | — | — | — | — | — | — | — |
| Change in accounts receivable | $96.7M | -$18.2M | $561.0K | $6.3M | $2.4M | -$1.6M | -$8.1M | $710.0K |
| Purchases of investments | $0 | $9.8M | $62.8M | $39.5M | $211.1M | $19.2M | $16.2M | $36.2M |
| Sales/maturities of investments | $11.5M | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $170.4M | $83.3M | $90.2M | $112.7M | $470.3M |
| Operating income | -$161.2M | -$233.3M | -$268.1M | -$262.9M | $160.0M |
| Net income | -$193.9M | -$227.1M | -$263.5M | -$280.3M | $127.8M |
| EPS (diluted) | $-3.76 | $-4.59 | $-6.02 | $-6.50 | $2.91 |
| EPS (basic) | $-3.76 | $-4.59 | $-6.02 | $-6.50 | $3.01 |
| Operating margin | -$95 | -$280 | -$297 | -$233 | $34 |
| Net margin | -$114 | -$273 | -$292 | -$249 | $27 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $453.0M | $466.0M | $574.0M | $833.3M | $1.11B |
| Total liabilities | $350.3M | $206.3M | $262.2M | $317.1M | $349.6M |
| Stockholders' equity | $102.7M | $259.7M | $311.7M | $516.2M | $764.3M |
| Total current assets | $281.3M | $278.0M | $335.0M | $416.0M | $518.8M |
| Total current liabilities | $118.1M | $103.2M | $130.3M | $130.4M | $130.5M |
| Cash & equivalents | $34.5M | $57.5M | $34.5M | $97.0M | $345.2M |
| Marketable securities (current) | $195.6M | $177.2M | $240.7M | $267.7M | $112.2M |
| Accounts receivable | $26.4M | $20.5M | $24.8M | $28.1M | $32.4M |
| Other current assets | $12.9M | $13.8M | $20.4M | $9.4M | $10.2M |
| Marketable securities (non-current) | $10.8M | $10.2M | $38.9M | $200.6M | $391.9M |
| Property, plant & equipment | $104.9M | $117.6M | $132.1M | $141.7M | $131.5M |
| Other non-current assets | $4.6M | $4.0M | $4.8M | $6.4M | $6.4M |
| Accounts payable | $21.4M | $22.8M | $22.8M | $27.2M | $11.4M |
| Deferred revenue (current) | $10.5M | $115.0K | $148.0K | $1.8M | $3.3M |
| Other non-current liabilities | $638.0K | $3.6M | $6.2M | $8.8M | $745.0K |
| Common stock & paid-in capital | $5.0K | $5.0K | $4.0K | $4.0K | $4.0K |
| Retained earnings | -$1.13B | -$932.1M | -$705.0M | -$441.6M | -$161.2M |
| Accumulated other comprehensive income (loss) | -$687.0K | -$741.0K | -$4.4M | -$15.4M | -$2.6M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$124.0M | -$173.1M | -$218.4M | -$207.5M | $218.9M |
| Investing cash flow | -$15.9M | $103.4M | $190.9M | -$11.9M | -$406.6M |
| Financing cash flow | $116.8M | $92.7M | -$35.0M | -$28.8M | $195.2M |
| Free cash flow | -$126.4M | -$175.6M | -$228.4M | -$238.2M | $134.7M |
| Capital expenditures | $2.4M | $2.4M | $10.0M | $30.7M | $84.2M |
| Share-based compensation | $34.6M | $38.5M | $40.3M | $40.8M | $38.8M |
| Deferred income taxes | — | — | — | — | — |
| Change in accounts receivable | $7.7M | -$9.7M | -$3.9M | -$4.8M | -$14.1M |
| Purchases of investments | $332.6M | $190.1M | $86.6M | $184.9M | $498.1M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding RGNX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 31 filers
Held by These Filers69.4%
Shares Outstanding52,820,000
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| BlackRock, Inc. | 6,397,440 | $76.6M | 12.11% | +10.6% | 2026-08-07 |
| Redmile Group, LLC | 4,368,804 | $52.3M | 8.27% | +0.0% | 2026-08-14 |
| State Street Corp | 2,971,173 | $35.6M | 5.63% | +8.8% | 2026-08-07 |
| Jpmorgan Chase & Co | 2,214,169 | $26.2M | 4.19% | -36.4% | 2026-08-12 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,107,557 | $25.2M | 3.99% | +5.0% | 2026-06-30 |
| Morgan Stanley | 1,953,237 | $23.4M | 3.70% | -5.5% | 2026-08-11 |
| Goldman Sachs Group Inc | 1,421,453 | $17.0M | 2.69% | -22.7% | 2026-08-14 |
| AQR CAPITAL MANAGEMENT LLC | 1,378,358 | $16.5M | 2.61% | +31.1% | 2026-08-14 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1,355,554 | $16.2M | 2.57% | +33.0% | 2026-06-30 |
| MARSHALL WACE, LLP | 1,284,950 | $15.4M | 2.43% | +0.0% | 2026-08-13 |
| GEODE CAPITAL MANAGEMENT, LLC | 1,241,296 | $14.9M | 2.35% | +9.1% | 2026-08-12 |
| Integral Health Asset Management, LLC | 800,000 | $9.6M | 1.51% | -46.7% | 2026-08-14 |
| Nuveen, LLC | 740,026 | $8.9M | 1.40% | +27.1% | 2026-08-11 |
| DIMENSIONAL FUND ADVISORS LP | 731,586 | $8.8M | 1.39% | -27.6% | 2026-08-11 |
| D. E. Shaw & Co., Inc. | 712,814 | $8.5M | 1.35% | +149.2% | 2026-08-14 |
| TWO SIGMA INVESTMENTS, LP | 669,808 | $8.0M | 1.27% | +20.7% | 2026-08-07 |
| CITADEL ADVISORS LLC | 669,023 | $8.0M | 1.27% | +0.0% | 2026-08-14 |
| Stifel Financial Corp | 560,727 | $6.7M | 1.06% | +42.8% | 2026-08-12 |
| Bank Of America Corp /De/ | 518,545 | $6.2M | 0.98% | +59.6% | 2026-08-14 |
| 22NW, LP | 492,759 | $5.9M | 0.93% | +0.0% | 2026-07-14 |
| MILLENNIUM MANAGEMENT LLC | 480,762 | $5.8M | 0.91% | +68.6% | 2026-08-14 |
| Pale Fire Capital SE | 466,209 | $5.6M | 0.88% | -5.6% | 2026-08-13 |
| Northern Trust Corp | 421,839 | $5.1M | 0.80% | +7.2% | 2026-08-12 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 396,450 | $4.7M | 0.75% | +1.5% | 2026-08-14 |
| Sixth Street Partners Management Company, L.P. | 396,450 | $4.7M | 0.75% | +0.0% | 2026-08-13 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-12-31 to 2026-09-01
Recent transactions
- Insiders have net bought 28,800 shares over the last 182 days, across 2 purchases and 4 sales.
- Most recent: Malzahn Craig (Chief Technology Officer) — Tax withholding of 234 shares on 2026-09-01.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)102,603 sh(2 txns)
Sales (open market)73,803 sh(4 txns)
Net Shares+28,800
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Malzahn Craig | Chief Technology Officer | Tax withholding | 2026-09-01 | 234 |
| Chan Mitchell | Chief Financial Officer | Tax withholding | 2026-09-01 | 4,902 |
| Ciongoli Gregory Austin | Reporting person | Open market purchase | 2026-08-27 | 53,407 |
| PAKOLA STEVE | Chief Medical Officer | Tax withholding | 2026-08-01 | 7,468 |
| Christmas Patrick J. | Chief Strategy & Legal Officer | Tax withholding | 2026-08-01 | 4,699 |
| Simpson Curran | Chief Executive Officer | Tax withholding | 2026-07-01 | 6,818 |
| Tasse Daniel | Reporting person | Grant / award | 2026-05-29 | 9,807 |
| STUMP DAVID C | Reporting person | Grant / award | 2026-05-29 | 9,807 |
| Zachary Jennifer | Reporting person | Grant / award | 2026-05-29 | 9,807 |
| Mills Kenneth T. | Reporting person | Grant / award | 2026-05-29 | 9,807 |
| MIGAUSKY GEORGE V | Reporting person | Grant / award | 2026-05-29 | 9,807 |
| KARABELAS ARGERIS N | Reporting person | Grant / award | 2026-05-29 | 9,807 |
| Glucksmann Alexandra | Reporting person | Grant / award | 2026-05-29 | 9,807 |
| Fox Allan M. | Reporting person | Grant / award | 2026-05-29 | 9,807 |
| Bennett Jean | Reporting person | Grant / award | 2026-05-29 | 9,807 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-01 | Malzahn Craig | Chief Technology Officer | Tax withholding | 234 | $9.32 |
| 2026-09-01 | Chan Mitchell | Chief Financial Officer | Tax withholding | 4,902 | $9.32 |
| 2026-08-27 | Ciongoli Gregory Austin | Reporting person | Open market purchase | 53,407 | $9.36 |
| 2026-08-26 | Ciongoli Gregory Austin | Reporting person | Open market purchase | 49,196 | $9.14 |
| 2026-08-25 | Ciongoli Gregory Austin | Reporting person | Grant / award | 15,432 | $0.00 |
| 2026-08-01 | PAKOLA STEVE | Chief Medical Officer | Tax withholding | 7,468 | $9.69 |
| 2026-08-01 | Christmas Patrick J. | Chief Strategy & Legal Officer | Tax withholding | 4,699 | $9.69 |
| 2026-07-02 | PAKOLA STEVE | Chief Medical Officer | Option exercise | 2,161 | $7.86 |
| 2026-07-02 | PAKOLA STEVE | Chief Medical Officer | Open market sale | 2,161 | $13.64 |
| 2026-07-01 | Simpson Curran | Chief Executive Officer | Tax withholding | 6,818 | $13.09 |
| 2026-07-01 | PAKOLA STEVE | Chief Medical Officer | Option exercise | 36,725 | $7.86 |
| 2026-07-01 | PAKOLA STEVE | Chief Medical Officer | Open market sale | 36,725 | $12.86 |
| 2026-06-30 | Simpson Curran | Chief Executive Officer | Grant / award | 1,453 | $10.18 |
| 2026-06-29 | PAKOLA STEVE | Chief Medical Officer | Open market sale | 19,608 | $11.04 |
| 2026-05-29 | Tasse Daniel | Reporting person | Grant / award | 9,807 | $0.00 |
| 2026-05-29 | STUMP DAVID C | Reporting person | Grant / award | 9,807 | $0.00 |
| 2026-05-29 | Zachary Jennifer | Reporting person | Grant / award | 9,807 | $0.00 |
| 2026-05-29 | Mills Kenneth T. | Reporting person | Grant / award | 9,807 | $0.00 |
| 2026-05-29 | MIGAUSKY GEORGE V | Reporting person | Grant / award | 9,807 | $0.00 |
| 2026-05-29 | KARABELAS ARGERIS N | Reporting person | Grant / award | 9,807 | $0.00 |
| 2026-05-29 | Glucksmann Alexandra | Reporting person | Grant / award | 9,807 | $0.00 |
| 2026-05-29 | Fox Allan M. | Reporting person | Grant / award | 9,807 | $0.00 |
| 2026-05-29 | Bennett Jean | Reporting person | Grant / award | 9,807 | $0.00 |
| 2026-05-11 | PAKOLA STEVE | Chief Medical Officer | Open market sale | 15,309 | $11.02 |
| 2026-03-10 | PAKOLA STEVE | Chief Medical Officer | Open market sale | 5,124 | $10.35 |
| 2026-02-01 | Christmas Patrick J. | Chief Strategy & Legal Officer | Tax withholding | 4,700 | $11.16 |
| 2026-02-01 | PAKOLA STEVE | Chief Medical Officer | Tax withholding | 5,267 | $11.16 |
| 2026-01-27 | Mills Kenneth T. | Reporting person | Option exercise | 225,000 | $13.09 |
| 2026-01-27 | Mills Kenneth T. | Reporting person | Tax withholding | 221,753 | $13.41 |
| 2026-01-06 | PAKOLA STEVE | Chief Medical Officer | Grant / award | 65,847 | $0.00 |
| 2026-01-06 | Malzahn Craig | Chief Technology Officer | Grant / award | 65,847 | $0.00 |
| 2026-01-06 | Simpson Curran | Chief Executive Officer | Grant / award | 144,864 | $0.00 |
| 2025-12-31 | Simpson Curran | Chief Executive Officer | Grant / award | 951 | $7.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 09:14 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-16 | 8-K | 2026-10-14 | View on SEC.gov → |
| 2026-09-23 | 8-K | 2026-09-23 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-08-27 | 4 | 2026-08-25 | View on SEC.gov → |
| 2026-08-25 | 8-K | 2026-08-25 | View on SEC.gov → |
| 2026-08-24 | 8-K | 2026-08-24 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-08-04 | 4 | 2026-08-01 | View on SEC.gov → |
| 2026-08-04 | 4 | 2026-08-01 | View on SEC.gov → |
| 2026-07-20 | 8-K | 2026-07-16 | View on SEC.gov → |
Recent news
Headlines about RGNX (REGENXBIO Inc.). Links open the publisher — we don’t host full articles.
-
REGENXBIO Eyes Q4 Pivotal Readout for One-Time Wet AMD Gene Therapy
Yahoo · 2026-10-21 -
REGENXBIO Inc. (RGNX) Discusses Clinical Program Progress and Commercial Outlook in Wet AMD and Rare Diseases Transcript
SeekingAlpha · 2026-10-21 -
REGENXBIO schedules October 20 event: REGENXBIO stock gains 8.87 percent
AD HOC NEWS · 2026-10-20 -
RGNX Nov 2026 7.000 put (RGNX261120P00007000) stock price, news, quote and history
Yahoo Finance UK · 2026-10-18 -
Barclays keeps USD 12.00 target for REGENXBIO stock
AD HOC NEWS · 2026-10-17 -
RGNX Stock Slumps 15% After-Hours — What’s Driving The Selloff?
Stocktwits · 2026-10-17 -
RGNX Oct 2026 16.000 call (RGNX261016C00016000) interactive stock chart
Yahoo Finance UK · 2026-10-17 -
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy
Stocktwits · 2026-10-16
No headlines in this category right now — try “All”.